ALK and non-small cell lung carcinoma: From January 2015 to September 2016, a total of 1714 patients with advanced NSCLC underwent testing for EGFR, KRAS, BRAF, ALK and ROS1.The results showed that there were 809 patients(47.2%) with EGFR mutations,149(7.8%) with KRAS mutations,19(1.1%) with BRAF mutations,106(6.2%) with ALK rearrangements, 43(2.5%) with ROS1 rearrangements, and 16 patients (0.9%) with multiple positive results.